GSK CEO Emma Walmsley with Endpoints' Drew Armstrong at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)
November 6, 2024 01:49 PM EST
People
China
AI
Pharma

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Drew Armstrong

Executive Editor

De­spite the rise of a vac­cine skep­tic in the cam­paign of US pres­i­den­tial elec­tion win­ner Don­ald Trump, GSK CEO Em­ma Walm­s­ley be­lieves her com­pa­ny can …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times